BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36291784)

  • 1. Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial.
    Ladbury C; Hao C; Ruel C; Liu J; Glaser S; Amini A; Wong J; Paz I; Leong L; Morgan R; Margolin K; Shibata S; Frankel P; Somlo G; Dandapani S
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
    Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
    Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
    Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
    Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
    Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
    Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
    Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
    Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: A single-center study.
    He X; Zhang P; Li Z; Bi F; Xu F; Wang X; Shen Y; Li Q; Qiu M
    Medicine (Baltimore); 2018 Oct; 97(40):e12601. PubMed ID: 30290630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
    van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
    Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
    Hasselle MD; Haraf DJ; Rusthoven KE; Golden DW; Salgia R; Villaflor VM; Shah N; Hoffman PC; Chmura SJ; Connell PP; Vokes EE; Weichselbaum RR; Salama JK
    J Thorac Oncol; 2012 Feb; 7(2):376-81. PubMed ID: 22198429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining Oligometastatic Bladder Cancer: A Systematic Review.
    Bamias A; Stenzl A; Zagouri F; Andrikopoulou A; Hoskin P
    Eur Urol Open Sci; 2023 Sep; 55():28-37. PubMed ID: 37662704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer.
    Scorsetti M; Franceschini D; De Rose F; Comito T; Villa E; Iftode C; Navarria P; D'Agostino GR; Masci G; Torrisi R; Testori A; Tinterri C; Santoro A
    Breast; 2016 Apr; 26():11-7. PubMed ID: 27017237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.
    Mimoto R; Kobayashi T; Imawari Y; Kamio M; Kato K; Nogi H; Toriumi Y; Hirooka S; Uchida K; Takeyama H
    Breast Cancer Res Treat; 2014 Sep; 147(2):317-24. PubMed ID: 25156580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.
    Zelefsky MJ; Yamada Y; Greco C; Lis E; Schöder H; Lobaugh S; Zhang Z; Braunstein S; Bilsky MH; Powell SN; Kolesnick R; Fuks Z
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):672-679. PubMed ID: 33422612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.
    Hu X; Li H; Liu H; Liu Z; Xia T; Zhang J; Wang Y
    Transl Cancer Res; 2021 Jan; 10(1):184-194. PubMed ID: 35116250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC.
    Farooqi A; Ludmir EB; Mitchell KG; Antonoff MB; Tang C; Lee P; Chang J; Elamin Y; Gomez DR; Gandhi SJ
    Radiother Oncol; 2021 Oct; 163():114-118. PubMed ID: 34419505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
    Kent CL; McDuff SGR; Salama JK
    Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
    Milano MT; Katz AW; Zhang H; Huggins CF; Aujla KS; Okunieff P
    Radiother Oncol; 2019 Feb; 131():45-51. PubMed ID: 30773186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
    Steenbruggen TG; Schaapveld M; Horlings HM; Sanders J; Hogewoning SJ; Lips EH; Vrancken Peeters MT; Kok NF; Wiersma T; Esserman L; van 't Veer LJ; Linn SC; Siesling S; Sonke GS
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.